Release Date: January 15, 2026

Expiration Date: February 15, 2026

Activity Overview

This educational activity is an archive of the live presentation held on January 8, 2026.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, gastroenterologists, advanced practice providers, nurses, and other health care practitioners involved in the treatment and management of gastrointestinal cancers.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Review the epidemiology, risk factors, pathophysiology, and diagnostic principles essential to early recognition of squamous cell anal carcinoma (SCAC)
Interpret recent clinical trial data and guideline recommendation updates to inform individualized care planning and optimize therapeutic sequencing in SCAC
Evaluate the safety and efficacy data of emerging immune checkpoint inhibitors in SCAC

Cases and Conversations: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Cases and Conversations: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

GET STARTED WITH THIS PROGRAM:

Related Content